BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $331.76, for a total value of $220,288.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $325.00, for a total transaction of $107,900.00.
• On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32.

BeOne Medicines Stock Up 5.5%

Shares of NASDAQ ONC traded up $17.52 during trading on Friday, reaching $337.89. 666,560 shares of the stock were exchanged, compared to its average volume of 405,360. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $174.74 and a twelve month high of $385.22. The company has a market capitalization of $37.05 billion, a price-to-earnings ratio of 662.53 and a beta of 0.47. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $327.41 and its 200 day moving average price is $312.68.

Analysts Set New Price Targets

Several research firms have commented on ONC. Citizens Jmp raised their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $405.00 price target on shares of BeOne Medicines in a research note on Thursday. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $367.36.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Primecap Management Co. CA acquired a new position in shares of BeOne Medicines during the second quarter worth approximately $1,231,720,000. Capital International Investors boosted its holdings in shares of BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after acquiring an additional 161,052 shares during the period. Temasek Holdings Private Ltd purchased a new position in BeOne Medicines during the second quarter valued at approximately $244,603,000. Marshall Wace LLP purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $113,190,000. Finally, Bank of America Corp DE grew its holdings in shares of BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock worth $117,629,000 after purchasing an additional 65,763 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.